ImmuRaid-CEA data

A Phase III study sponsored by IMMU (Morris Plains, N.J.) and reported in the Journal of Clinical Oncology showed that ImmuRaid-CEA accurately diagnosed recurrence in 93 percent of 16 patients, 15 of whom underwent exploratory surgery. ...